39 papers

• 1 to 23 files per paper, with a mean average of 8 files per paper.
• 6 to 189 figures or tables per paper, with a mean average of 47 figures or tables per paper.
• 20 to 65,451 data points per paper, with a mean average of 14,780 data points per paper.

---

81,356 unique gene lookup values

• 1 to 139 entries per gene, with a mean average of 6.8 entries per gene.
• 1 to 19 studies per gene, with a mean average of 2.8 studies per gene.

---

11 diseases

• 26 Parkinson diseaseParkinson disease
•  6 Alzheimer disease
•  4 dementia with Lewy bodies / Lewy body disease
•  3 progressive supranuclear palsy
•  2 multiple sclerosis
•  2 neurodegenerative disease, NOS
•  1 Huntington disease
•  1 multiple system atrophy
•  1 post-traumatic stress disorder
•  1 schizophrenia
•  1 temporal lobe epilepsy

values are number of studies with

---

18 categories

• 27 disease-control
• 13 cell type
• 10 cell marker
•  7 genetics
•  6 control
•  5 disease
•  5 neuropathology
•  4 mechanistic
•  3 control-control
•  3 disease-disease
•  3 subject information
•  2 brain region
•  1 case study
•  1 cognition
•  1 development
•  1 experimental condition
•  1 medication
•  1 motor

values are number of studies with

---

16 regions, tissues, or models

• 7 prefrontal cortex
• 5 frontal cortex
• 4 blood
• 4 entorhinal cortex
• 4 iPSCs
• 4 substantia nigra
• 3 brain white matter
• 3 midbrain
• 3 temporal cortex
• 2 genetics
• 1 caudate nucleus
• 1 embryo ventral midbrain
• 1 globus pallidus
• 1 putamen
• 1 striatum
• 1 urine

---

16 study approaches

•   RNA-seq
• • 16 RNA-seq
  •  8 snRNA-seq
  •  4 scRNA-seq
  •  1 lrRNA-seq
  •  1 spatial transcriptomics
•   proteomics
• •  7 LC MS/MS proteomics
  •  1 MS3 proteomics
  •  1 Olink proteomics
  •  1 SomaScan proteomics
•   other
• •  8 computational
  •  3 microarray
  •  3 GWAS
  •  2 immunofluorescence
  •  1 western blot

values are number of studies with

PARK-seq provides a unifying database for molecular studies on neurodegenerative disease in humans. Part of the detail-oriented approach that makes PARK-seq unique includes:

• Standardization of names
  • Gene, non-coding products, and protein symbols are standardized across over a decade of studies through meticulous database cross-referencing and dogged searches.
• Clear formatting
  • Increases and decreases are immediately evident and standardized across studies (ex. Disease vs control, more severe pathology vs less severe)
• Cohort and study details
  • Key details of each study are embedded in the table allowing for comparison of disparate results within the framework of cohort: age, disease, biological sex, geographical region, and neuropathology; as well as, experiment: substrate extraction and purification, sequencing technology, post-processing, and statistical analysis.
  • Additionally, detailed notes are provided covering errors, confusing text, and missing data.
• Detailed filtering tools
  • The database can be searched for any string, or filtered using buttons that cover every item included in the table.
• Manual curation
  • A molecular neuroscientist hand-curates all information, increasing accuracy and allowing for meticulous cross-referencing to derive as much information as possible on cohort demographics. This approach is also used for the gene standardization, allowing for recording of disparities where found.

• PARK-seq [Internet]. Phoenix (AZ, USA). 2026 March 23 [updated 2026 May 25; cited {YEAR} {MONTH} {DAY}]. Available from: https://parkseq.com.


• Kelley CM, Manfredsson FP. PARK-seq [Internet]. Phoenix (AZ, USA): CMK Data and Barrow Neurological Institute. 2026 March 1 [updated 2026 May 25; cited {YEAR} {MONTH} {DAY}]. Available from: https://parkseq.com.